HCPs who prescribe, monitor and oversee the management / or provide in person medical supervision of patients on Mayzent (siponimod).

Patients/Caregivers of patients who are taking Mayzent (siponimod) to treat their MS and according to the prescription of their neurologists across EU countries and Canada that were included in the launch program

Percentage of HCPs and patients/caregivers who report receive and reading of the educational materials to be collected

Knowledge and understanding of the HCPs as per detailed in the educational information provided relating to:

• The appropriate initiation
• Specific safety measures when treating patients with Mayzent (siponimod)
• Steps when treating patients with sinus bradycardia, 1st/2nd degree AV block or history of myocardial infarction or health failure
• Procedures for the management of infections, macular edema, skin malignancies and pregnancy considerations.
• Steps in ophthalmology checklist, managing infection risk, pregnancy, liver function and skin examinations

Knowledge and understanding was measured according to the percentage of correct responses given across the sample, where 70% achieving the correct answer is deemed acceptable.

Knowledge and understanding of the patient/caregivers' as per detailed in the educational information provided relating to:

• Specific safety measures when being treated with Mayzent (siponimod)
• Side effects and potential risks

Knowledge and understanding was measured according to the percentage of correct responses given across the sample, where 70% achieving the correct answer is deemed acceptable.